Beam Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good afternoon. Thank you for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO of Beam Therapeutics. I'll now pass the mic to their CEO, John Evans, for a short presentation, followed by a live audience Q&A.
John, the stage is yours.
Thank you very much. So yes, my name is John Evans, here to tell you about Beam Therapeutics and some of our medicines. And I'm going to talk about the power of predictability in the technology that we're using. So as a reminder, I will be making forward-looking statements today.
So at Beam, our vision is to provide lifelong cures for patients suffering from serious diseases. This is gene editing for rare and common disorders. This means the potential for onetime curative therapies with lifelong effects. And this is a platform that can potentially create a large number of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
